Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 5/20 | 0.35 |
| ▸ | CDK1 | P06493 | 4/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.35 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.35 |
| ▸ | CDK9 | P50750 | 4/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | GPR183 | P32249 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL351556 | 0.85 | ADORA2A (0.37) | ADORA3ADORA2AADORA1GPR183JAK1 | |
| SCHEMBL352615 | 0.82 | PDE9A (0.40) | ADORA3ADORA2AADORA1GPR183 | |
| SCHEMBL351991 | 0.80 | ALDH1A1 (0.35) | ROCK1ADORA3ADORA2AADORA1GPR183 | |
| SCHEMBL1306340 | 0.77 | IRAK4 (0.43) | IRAK4 | |
| SCHEMBL351895 | 0.77 | IRAK4 (0.43) | IRAK4 | |
| SCHEMBL4420185 | 0.76 | ROCK1 (0.49) | TNNI3KROCK1CDK2CDK1CCNB1 | |
| SCHEMBL351023 | 0.75 | ADORA3 (0.45) | CCND3CDK6ADORA3ADORA2AADORA1 | |
| SCHEMBL370217 | 0.74 | ADORA3 (0.34) | CNR2ADORA3ADORA2AADORA1GPR183 | |
| SCHEMBL10171253 | 0.71 | ADORA3 (0.53) | TNNI3KCDK2CDK1CCNB1CCNT1 | |
| SCHEMBL352724 | 0.69 | SYK (0.37) | ROCK1CDK2CDK1CDK5JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960372-B1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | claimed |
| EP-1960372-A1 | KINASE INHIBITORS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2008-08-27 | — | — | EP | claimed |
| WO-2007070872-A1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | claimed |
| US-9834568-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | MIDCAP FINANCIAL TRUST | 2016-01-28 | — | — | US | disclosed |
| EP-1960372-B1 | KINASE INHIBITORS AND THEIR USES | RIGEL PHARMACEUTICALS INC (US) | 2015-12-09 | — | — | EP | disclosed |
| US-9096542-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8053434-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-7601713-B2 | Kinase inhibitors and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015937-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | TNNI3K 79/4885CNR2 4297/4885ROCK1 208/4885 |
| US-20160024116-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | TNNI3K 79/4885CNR2 4297/4885ROCK1 208/4885 |
| US-20100069369-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, JAK2 | TNNI3K 49/4885CNR2 3336/4885ROCK1 117/4885 |
| US-20070142402-A1 | Kinase Inhibitors And Their Uses | BTK, SYK, LYN | TNNI3K 79/4885CNR2 4297/4885ROCK1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.